Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 6:5:191.
doi: 10.3389/fimmu.2014.00191. eCollection 2014.

Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens

Harm Westdorp  1 , Annette E Sköld  2 , Berit A Snijer  2 , Sebastian Franik  2 , Sasja F Mulder  3 , Pierre P Major  4 , Ronan Foley  4 , Winald R Gerritsen  3 , I Jolanda M de Vries  1
Affiliations
Review

Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens

Harm Westdorp et al. Front Immunol. .

Abstract

Prostate cancer (PCa) is the most common cancer in men and the second most common cause of cancer-related death in men. In recent years, novel therapeutic options for PCa have been developed and studied extensively in clinical trials. Sipuleucel-T is the first cell-based immunotherapeutic vaccine for treatment of cancer. This vaccine consists of autologous mononuclear cells stimulated and loaded with an immunostimulatory fusion protein containing the prostate tumor antigen prostate acid posphatase. The choice of antigen might be key for the efficiency of cell-based immunotherapy. Depending on the treatment strategy, target antigens should be immunogenic, abundantly expressed by tumor cells, and preferably functionally important for the tumor to prevent loss of antigen expression. Autoimmune responses have been reported against several antigens expressed in the prostate, indicating that PCa is a suitable target for immunotherapy. In this review, we will discuss PCa antigens that exhibit immunogenic features and/or have been targeted in immunotherapeutic settings with promising results, and we highlight the hurdles and opportunities for cancer immunotherapy.

Keywords: CRPC; immunotherapy; immunotherapy of cancer; prostate cancer; tumor-associated antigens.

PubMed Disclaimer

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin (2009) 59(4):225–4910.3322/caac.20006 - DOI - PubMed
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 49(6):1374–40310.1016/j.ejca.2012.12.027 - DOI - PubMed
    1. Risk M, Corman JM. The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol (2009) 11(1):16–27 - PMC - PubMed
    1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 351(15):1502–1210.1056/NEJMoa040720 - DOI - PubMed
    1. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 26(2):242–510.1200/JCO.2007.12.4008 - DOI - PubMed